DEX international M&A advised IDB Holland on the sale to Advanced Accelerator Applications

DEX international M&A advised IDB Holland on the sale to Advanced Accelerator Applications

Advanced Accelerator Applications S.A. from New York (Nasdaq: AAAP), an international specialist in Molecular Nuclear Medicine announced today that it has acquired 100% of the shares of the IDB Group. The IDB Group includes IDB Holland bv, IDB Radiopharmacy bv and Beheermaatschappij Weelde bv and is a leading manufacturer of Lutetium 177 (Lu-177). IDB produces, markets and sells Lu-177 under the brand name LuMark®, and has established this product as the leading brand of Lutetium 177 worldwide. LuMark® is the only Lu-177 product to have received European Marketing Authorization.

Acquiring the IDB Group will enable AAA to own the leading global supplier of Lu-177 for Lutathera and build its own Lu-177 manufacturing business. This acquisition strengthens AAA’s leadership position in the European market and is in line with the company’s vertical integration strategy.

Stefano Buono, Chief Executive Officer of AAA commented: “We believe that our key product candidate Lutathera has the potential to dramatically shift the treatment paradigm for patients with progressive neuroendocrine tumors and improve the standard of care for this disease. With this shift in treatment, Lu-177 chloride has a significant opportunity to be recognized as an important radiopharmaceutical precursor.

The IDB Group, located in Baarle-Nassau, the Netherlands, is the leading international isotope manufacturer and supplier. The company is active in over 25 countries. Products distributed by IDB include a Ge-68/Ga-68 generator, which is used in state-of-the-art PET peptide imaging such as Somakit.

Advanced Accelerator Applications (AAA) is a radiopharmaceutical company that develops innovative diagnostic and therapeutic products. AAA’s main focus is in the field of molecular imaging and targeted, individualized therapy for patients with serious conditions (“Personalized Medicine”). AAA currently has 17 production and R&D facilities able to manufacture both diagnostics and therapeutic MNM products, and has over 390 employees in 11 countries (France, Italy, UK, Germany, Switzerland, Spain, Poland, Portugal, Israel, U.S. and Canada). AAA is listed on the Nasdaq Global Select Market under the ticker “AAAP”.

DEX International M&A acted as advisor to the shareholders of IDB Group.

Tombstone IDB